Follistatin 344 vs Gonadorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Follistatin 344
Follistatin 344 is a 344-amino acid isoform of follistatin — an endogenous glycoprotein that functions primarily as a myostatin and activin inhibitor. Myostatin (GDF-8) is the body's primary muscle growth suppressor; follistatin binds and neutralizes it with high affinity, removing this brake on muscle protein synthesis. Research and animal data show dramatic increases in muscle fiber size and strength when follistatin is elevated or myostatin is inhibited.
Full profileGonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profile| Follistatin 344 | Gonadorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | FST-344, Follistatin isoform 344, FST | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse |
| Evidence | Research-stage | Research-stage |
| Dosing range | 50mcg–200mcg mcg, Once daily or every other day for 10–30 day cycles | 50mcg–200mcg mcg, 2–3x per week subcutaneous |
| Administration | Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis) | Subcutaneous injection, Intranasal (pulsatile delivery) |
| Key side effects | Potential FSH suppression (reproductive effects in females — may affect menstrual cycle), Accelerated hair follicle cycling (Wnt pathway involvement — theoretical hair loss concern at high doses), Joint discomfort with rapid muscle tissue growth, Limited long-term human safety data | Injection site reactions, Headache, Nausea, Flushing |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Follistatin 344 — Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis); Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery).
- Frequency: Follistatin 344 is typically Once daily or every other day for 10–30 day cycles; Gonadorelin is 2–3x per week subcutaneous.
- Research depth: this profile cites 3 sources for Follistatin 344 vs 2 for Gonadorelin.
How each works
Follistatin 344
Follistatin's muscle effects were dramatically illustrated when mice and cattle with follistatin overexpression or myostatin knockouts developed 2–3x normal muscle mass. Human follistatin gene therapy trials (AAV-mediated) are ongoing for Becker Muscular Dystrophy, showing sustained myostatin inhibition and improved muscle function over years from a single injection. Follistatin also inhibits activin A and B (involved in muscle wasting during illness), FSH secretion (reproductive effects), and inflammatory cytokines. The 344 isoform has an extended heparin-binding domain that increases tissue retention compared to the shorter FST-288 isoform.
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.